AstraZeneca today announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments..

阿斯利康今天宣布成功完成对Fusion Pharmaceuticals Inc.的收购，Fusion Pharmaceuticals Inc.是一家临床阶段的生物制药公司，开发下一代放射性结合物（RCs）。此次收购标志着阿斯利康迈出了重要的一步，它实现了用更有针对性的治疗替代传统的化疗和放疗方案，从而改变癌症治疗和患者预后的雄心壮志。。

This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca.

此次收购补充了阿斯利康领先的肿瘤学组合，增加了RCs的融合管道，包括他们最先进的计划FPI-2265，这是一种针对转移性去势抵抗性前列腺癌（mCRPC）患者的潜在新疗法，并为阿斯利康带来了新的专业知识和基于锕的RCs的开创性研发，制造和供应链能力。

It also strengthens AstraZeneca’s presence in and commitment to Canada..

它还加强了阿斯利康在加拿大的存在和对加拿大的承诺。。

As a result of the acquisition, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US.

收购的结果是，Fusion已成为阿斯利康的全资子公司，在加拿大和美国运营。

Financial considerations

财务考虑

Under the terms of the definitive agreement, AstraZeneca, through a subsidiary, has acquired all of Fusion’s outstanding shares pursuant to a plan of arrangement for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone prior to 31st August, 2029.

根据最终协议的条款，阿斯利康通过其子公司，按照安排计划以收盘时每股21.00美元的现金价格，加上2029年8月31日之前达到规定监管里程碑时每股3.00美元的不可转让或有价值现金支付权，收购了Fusion的所有流通股。

Combined, the upfront payment and maximum potential contingent value payment, if achieved, represent a transaction value of approximately $2.4bn. As part of the transaction, AstraZeneca acquired the cash, cash equivalents and short-term investments on Fusion’s balance sheet, which totalled $211m as of 31st March 2024.

综合起来，预付款和最大潜在或有价值付款（如果实现）的交易价值约为24亿美元。作为交易的一部分，阿斯利康收购了Fusion资产负债表上的现金、现金等价物和短期投资，截至2024年3月31日，这些投资总额为2.11亿美元。

Fusion shares will be delisted from the Nasdaq Stock Market and deregistered under the U.S. Securities Exchange Act of 1934 and Fusion has applied to cease to be a reporting issuer under applicable Canadian securities laws..

Fusion股票将从纳斯达克股票市场退市，并根据1934年《美国证券交易法》注销登记，Fusion已根据适用的加拿大证券法申请停止作为报告发行人。。

Canadian Early Warning Disclosure

加拿大预警披露

Following completion of the acquisition, 15863210 Canada Inc. (the “Purchaser”), a wholly-owned, indirect subsidiary of AstraZeneca, has beneficial ownership and control over 85,692,265 Fusion shares, being 100% of the issued and outstanding Fusion shares. The value, in Canadian dollars, of the consideration paid per Fusion share and in total (representing, in each case the total of the upfront payment and maximum potential contingent value payment) was C$32.72 per share and C$2,804,219,198.25 in total (based on the Bank of Canada’s exchange rate as of June 3, 2024 being C$1.00 to $0.7334)..

收购完成后，15863210加拿大公司（“买方”）是阿斯利康的全资间接子公司，拥有85692265股Fusion股份的实益所有权和控制权，占已发行和流通的Fusion股份的100%。每股Fusion股份支付的对价和总对价（在每种情况下代表预付款和最大潜在或有价值支付的总额）的价值（以加元计）分别为每股32.72加元和总计2804219198.25加元（根据加拿大银行截至2024年6月3日的汇率为1.00加元至0.7334加元）。。

Fusion’s head office is located at 270 Longwood Road South Hamilton, Ontario, L8P 0A6. The Purchaser’s head office is located at Suite 4000 –199 Bay Street, Toronto, Ontario M5L 1A9.

Fusion总部位于安大略省汉密尔顿南朗伍德路270号，L8P 0A6。买方总部位于安大略省多伦多湾街199号4000室M5L 1A9。

All figures in this news release are denominated in United States dollars, unless otherwise stated.

除非另有说明，本新闻稿中的所有数字均以美元计价。

The disclosure in this section is being provided pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issuers of the Canadian Securities Administrators.  An early warning report will be filed under Fusion’s profile on SEDAR+ (www.sedarplus.ca) containing additional information respecting the foregoing matters.

本节中的披露是根据国家文书62-103–加拿大证券管理人的预警系统和相关接管投标和内幕报告发行人提供的。预警报告将在SEDAR+（www.sedarplus.ca）上的Fusion简介下提交，其中包含有关上述事项的其他信息。

Further information and a copy of the early warning report may be obtained by contacting the Investor Relations Team with contact details available here..

可通过联系投资者关系团队获得更多信息和预警报告副本，并在此处提供联系方式。。

Notes

注意事项

Radioconjugates in oncology

肿瘤学中的放射性结合物

Radioconjugates (RCs) combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells. By seeking out cancer cells, RCs provide a more precise mechanism of cancer cell killing compared with traditional radiation therapy, with the goal of improving efficacy while minimising toxicity on healthy cells.

放射性结合物（RCs）将抗体，小分子或肽的精确靶向与有效的医用放射性同位素结合起来，直接向癌细胞传递辐射。通过寻找癌细胞，与传统放射疗法相比，RCs提供了更精确的癌细胞杀伤机制，目的是提高疗效，同时最大限度地减少对健康细胞的毒性。

RCs are administered via systemic delivery, which enables their use in tumour types not accessible to external beam radiation and the targeting of cancer cells that have spread from the main tumour to other sites in the body..

RCs通过全身递送给药，这使得它们能够用于外部束辐射无法接近的肿瘤类型，并靶向从主要肿瘤扩散到体内其他部位的癌细胞。。

About FPI-2265

关于FPI-2265

FPI-2265 is an actinium-225 based PSMA-targeting RC for mCRPC, currently in a Phase II trial.

FPI-2265是一种基于锕225的PSMA，针对mCRPC的RC，目前正在进行II期试验。

Actinium-225 emits alpha particles and holds the promise of being a next-generation radioisotope in cancer treatment. By delivering a greater radiation dose over a shorter distance, alpha particles such as actinium-225 have the potential for more potent cancer cell killing, and targeted delivery, thereby minimising damage to surrounding healthy tissue..

锕-225发射α粒子，有望成为癌症治疗中的下一代放射性同位素。通过在较短距离内提供更大的辐射剂量，锕-225等α粒子有可能更有效地杀死癌细胞，并有针对性地传递，从而最大程度地减少对周围健康组织的损害。。

AstraZeneca in oncology

阿斯利康肿瘤学

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

阿斯利康（AstraZeneca）正在领导一场肿瘤学革命，致力于为各种形式的癌症提供治疗，遵循科学理解癌症及其复杂性，发现、开发并向患者提供改变生命的药物。

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

该公司专注于一些最具挑战性的癌症。正是通过不断的创新，阿斯利康建立了行业内最多样化的投资组合和渠道之一，有可能促进医学实践的变化并改变患者的体验。

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

阿斯利康的愿景是重新定义癌症护理，并有一天消除癌症作为死亡原因。

Forward-looking statements

前瞻性声明

This announcement may include statements that are not statements of historical fact, or “forward-looking statements,” including with respect to AstraZeneca’s acquisition of Fusion. Such forward looking statements include, but are not limited to, AstraZeneca’s beliefs and expectations and statements about the contingent milestone payment, benefits sought to be achieved in AstraZeneca’s acquisition of Fusion, the potential effects of the acquisition on AstraZeneca, as well as the expected benefits and success of FPI-2265 and other pipeline products or any combination product and the filing of the Purchaser’s early warning report on SEDAR+.

该公告可能包括非历史事实声明或“前瞻性声明”，包括关于阿斯利康收购Fusion的声明。此类前瞻性陈述包括但不限于阿斯利康的信念和期望，以及关于或有里程碑付款的陈述，阿斯利康收购Fusion所寻求实现的利益，收购对阿斯利康的潜在影响，以及FPI-2265和其他管道产品或任何组合产品的预期利益和成功，以及买方对SEDAR+的预警报告的提交。

These statements are based upon the current beliefs and expectations of AstraZeneca’s management and are subject to significant risks and uncertainties. There can be no guarantees that FPI-2265 or any other pipeline products will receive the necessary regulatory approvals or prove to be commercially successful if approved.

这些声明基于阿斯利康管理层目前的信念和期望，并且存在重大风险和不确定性。无法保证FPI-2265或任何其他管道产品将获得必要的监管批准，或在批准后证明其商业成功。

If underlying assumptions prove inaccurate or risks or uncertainties materialise, actual results may differ materially from those set forth in the forward-looking statements..

如果基础假设不准确或风险或不确定性成为现实，实际结果可能与前瞻性声明中规定的结果存在重大差异。。

Risks and uncertainties include, but are not limited to, the possibility that the achievement of the specified milestone described in the contingent value rights agreement may take longer to achieve than expected or may never be achieved and the resulting contingent milestone payment may never be realised; general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of COVID 19; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; competition from other products; and challenges inherent in new product development, including obtaining regulatory approval..

风险和不确定性包括但不限于实现或有价值权利协议中描述的特定里程碑可能需要比预期更长的时间才能实现，或者可能永远无法实现，并且可能永远无法实现由此产生的或有里程碑付款；一般行业条件和竞争；一般经济因素，包括利率和货币汇率波动；新型冠状病毒19的影响；美国和国际上制药行业监管和医疗保健立法的影响；来自其他产品的竞争；以及新产品开发中固有的挑战，包括获得监管部门的批准。。

AstraZeneca undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in AstraZeneca’s Annual Report on Form 20-F for the year ended 31st December 2023 and Fusion’s Annual Report on Form 10‑K for the year ended 31st December 2023 and Quarterly Report on Form 10-Q for the quarter ended 31st March, 2024, in each case as amended by any subsequent filings made with the SEC.

阿斯利康没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。可能导致结果与前瞻性声明中描述的结果存在重大差异的其他因素可以在阿斯利康的表20-F年度报告（截至2023年12月31日）和Fusion的表10-K年度报告（截至2023年12月31日）以及表10-Q季度报告（截至2024年3月31日的季度）中找到，在每种情况下，都可以通过向SEC提交的任何后续文件进行修订。

These and other filings made by AstraZeneca and Fusion with the SEC are available at www.sec.gov..

阿斯利康（AstraZeneca）和Fusion与SEC提交的这些文件和其他文件可在www.SEC.gov上查阅。。

AstraZeneca

阿斯利康

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, Respiratory & Immunology and Vaccines & Immune Therapies.

阿斯利康（LSE/STO/Nasdaq:AZN）是一家全球科学领先的生物制药公司，专注于肿瘤学，罕见病和生物制药（包括心血管，肾脏和代谢，呼吸和免疫学以及疫苗和免疫疗法）中处方药的发现，开发和商业化。

Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

阿斯利康总部位于英国剑桥，在100多个国家运营，其创新药物被全球数百万患者使用。请访问astrazeneca.com并在社交媒体@astrazeneca上关注该公司。